Vascular disrupting agents: a new avenue of research von Horsman, M.R

Volltext

Hyperthermia: a Potent Enhancer of Radiotherapy von Horsman, M.R, Overgaard, J

Volltext

623 Evaluating the Potential of OXi4503 to Enhance Tumour Response to Radiation Administered in Clinically Relevant Conventional or Stereotactic Schedules von Horsman, M.R

Volltext

OC-0235: Enhancing stereotactic radiation schedules using the vascular disrupting agent OXi4503 von Horsman, M.R, Wittenborn, T.R

Volltext

SP-0485 Hypofractionation from a radiobiological perspective von Horsman, M.R.

Volltext

Inhibiting the actions of cathepsin L effects both tumour initiation and metastasis formation von Wittenborn, T.R, Elming, P.B, Horsman, M.R

Volltext

219: Inhibition of tumour growth using the small molecule Cathepsin L inhibitor, KGP94 von Wittenborn, T, Horsman, M.R

Volltext

EP-2056: Preclinical investigation of hypoxia induced genes in different prostate cancer cell lines von Wittenborn, T, Nielsen, S, Busk, M, Horsman, M.R, Overgaard, J, Alsner, J, Sørensen, B.S

Volltext

104 - Vascular disrupting agents: a new avenue of research von Horsman, M.R.

Volltext

Robustness and reliability of PET-based identification and quantification of tumor hypoxia, using simple static or more complex scan acquisitions von Busk, M, Iversen, A.B, Petersen, J.B, Munk, O.L, Jakobsen, S, Frøkiær, J, Overgaard, J, Horsman, M.R

Volltext

RBE for Carbon ions In Vivo for Tumor Control and Normal Tissue Damage von Sørensen, B.S, Horsman, M.R, Alsner, J, Overgaard, J, Durante, M, Scholz, M, Friedrich, T, Bassler, N

Volltext

OC-0542: Biguanides and cancer: microenvironmental and antiproliferative effects at in vivo achievable concentrations von Iversen, A, Garm, C, Jakobsen, S, Jessen, N, Sundelin, E, Frøkiær, J, Horsman, M.R, Busk, M

Volltext

40: Do physiological relevant doses of biguanides have any role in cancer treatment? von Busk, M, Frøkiær, J, Horsman, M.R, Jakobsen, S, Jessen, N, Overgaard, J

Volltext

1160 POSTER Induction of Hypoxia by Vascular Disrupting Agents and the Significance for Their Combination With Radiation Therapy von Horsman, M.R, Busk, M, Overgaard, J

Volltext

Molecular and biological rationale of hyperthermia as radio- and chemosensitizer von Oei, A.L., Kok, H.P., Oei, S.B., Horsman, M.R., Stalpers, L.J.A., Franken, N.A.P., Crezee, J.

Volltext

OC-0202: Combining hyperthermia or a VDA with checkpoint inhibitors to increase tumour immunogenicity von Elming, P.B., Wittenborn, T.R., Horsman, M.R.

Volltext

PO-2209 Beneficial Effects Of Combining Hypofractionated Radiation Doses With Hyperthermia Temperature von Charlemagne Asonganyi, F., Sinha, P.M., Sitarz, M.K., Elming, P.B., Horsman, M.R.

Volltext

PO-2238 Improving immunotherapy outcome in solid tumor by combining with other established cancer treatments von Sinha, P., Asonganyi, F.C., Nygaard, S., Sitarz, M.K., Elming, P.B., Horsman, M.R.

Volltext

OC-0053: Combining hyperthermia and checkpoint inhibitors: a method of increasing tumour immunogenicity? von Elming, P.B., Wittenborn, T.R., Horsman, M.R.

Volltext

OC-0588 Combing hyperthermia and/or OXi4503 with low LET radiation is equivalent to high LET radiation alone von Elming, P.B., Sørensen, B.S., Spejlborg, H., Overgaard, J., Horsman, M.R.

Volltext